S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
NetApp stock is about to hit 20-year highs
New CBOE “special perk” helps traders target income every weekend (Ad)
Ambarella: robust double-digit upside comes into focus
Retail sector resurgence: optimism grows for holiday momentum
New CBOE “special perk” helps traders target income every weekend (Ad)
Behind the tech boom: Big price leaders selectively laying off
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
NetApp stock is about to hit 20-year highs
New CBOE “special perk” helps traders target income every weekend (Ad)
Ambarella: robust double-digit upside comes into focus
Retail sector resurgence: optimism grows for holiday momentum
New CBOE “special perk” helps traders target income every weekend (Ad)
Behind the tech boom: Big price leaders selectively laying off
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
NetApp stock is about to hit 20-year highs
New CBOE “special perk” helps traders target income every weekend (Ad)
Ambarella: robust double-digit upside comes into focus
Retail sector resurgence: optimism grows for holiday momentum
New CBOE “special perk” helps traders target income every weekend (Ad)
Behind the tech boom: Big price leaders selectively laying off
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
NetApp stock is about to hit 20-year highs
New CBOE “special perk” helps traders target income every weekend (Ad)
Ambarella: robust double-digit upside comes into focus
Retail sector resurgence: optimism grows for holiday momentum
New CBOE “special perk” helps traders target income every weekend (Ad)
Behind the tech boom: Big price leaders selectively laying off
These biotechs targeting multiple neurodegenerative diseases

Zai Lab Stock Price, News & Analysis (NASDAQ:ZLAB)

$27.50
+0.21 (+0.77%)
(As of 12/1/2023 ET)
Compare
Today's Range
$26.57
$28.03
50-Day Range
$22.97
$30.01
52-Week Range
$22.35
$49.81
Volume
509,301 shs
Average Volume
388,930 shs
Market Capitalization
$2.72 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$79.97

Zai Lab MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
190.8% Upside
$79.97 Price Target
Short Interest
Bearish
4.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of Zai Lab in the last 14 days
Based on 13 Articles This Week
Insider Trading
Acquiring Shares
$134,650 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.48) to ($2.84) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

506th out of 953 stocks

Pharmaceutical Preparations Industry

239th out of 448 stocks


ZLAB stock logo

About Zai Lab Stock (NASDAQ:ZLAB)

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.

ZLAB Stock Price History

ZLAB Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Analyst Ratings for Zai Lab
Zai Lab (NASDAQ:ZLAB) Shares Up 4.4%
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Zai Lab executive purchases 5,000 shares
Recap: Zai Lab Q3 Earnings
Zai Lab Ltd (1ZLB.SG)
The Latest Analyst Ratings for Zai Lab
Zai Lab Stock: De-Risking Through Market Tapping
See More Headlines
Receive ZLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/06/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ZLAB
Employees
2,036
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$79.97
High Stock Price Target
$128.00
Low Stock Price Target
$62.50
Potential Upside/Downside
+190.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-443,290,000.00
Net Margins
-114.22%
Pretax Margin
-114.22%

Debt

Sales & Book Value

Annual Sales
$215.04 million
Book Value
$8.91 per share

Miscellaneous

Free Float
93,670,000
Market Cap
$2.72 billion
Optionable
Optionable
Beta
1.06
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Ying Du Ph.D. (Age 57)
    Founder, Chairperson & CEO
    Comp: $1.67M
  • Mr. Joshua L. Smiley (Age 53)
    President & COO
    Comp: $647.11k
  • Dr. Rafael G. Amado M.D. (Age 59)
    President and Head of Global Oncology Research & Development
    Comp: $477k
  • Dr. Harald Reinhart M.D. (Age 71)
    President and Head of Global Development for Neuroscience, Autoimmune & Infectious Diseases
    Comp: $923.33k
  • Dr. Yajing Chen Ph.D.
    Chief Financial Officer
  • Dr. Peter Huang Ph.D.
    Chief Scientific Officer
  • Mr. Frazor Titus Edmondson III (Age 57)
    J.D., Chief Legal Officer & Corporate Secretary
    Comp: $829k
  • Ms. Ann E. Beasley J.D.
    Chief Compliance Officer
  • Dr. Ning Xu M.D. (Age 58)
    Executive VP & Head of Clinical Operations
  • Dr. Jonathan J. Wang MBA (Age 41)
    Ph.D., Chief Business Officer














ZLAB Stock Analysis - Frequently Asked Questions

Should I buy or sell Zai Lab stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZLAB shares.
View ZLAB analyst ratings
or view top-rated stocks.

What is Zai Lab's stock price target for 2024?

4 analysts have issued 1 year target prices for Zai Lab's stock. Their ZLAB share price targets range from $62.50 to $128.00. On average, they anticipate the company's stock price to reach $79.97 in the next twelve months. This suggests a possible upside of 190.8% from the stock's current price.
View analysts price targets for ZLAB
or view top-rated stocks among Wall Street analysts.

How have ZLAB shares performed in 2023?

Zai Lab's stock was trading at $30.70 at the start of the year. Since then, ZLAB shares have decreased by 10.4% and is now trading at $27.50.
View the best growth stocks for 2023 here
.

When is Zai Lab's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our ZLAB earnings forecast
.

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) issued its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.23. The company had revenue of $69.23 million for the quarter, compared to the consensus estimate of $67.12 million. Zai Lab had a negative trailing twelve-month return on equity of 31.19% and a negative net margin of 114.22%.

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

When did Zai Lab IPO?

(ZLAB) raised $100 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by many different institutional and retail investors. Top institutional investors include Invesco Ltd. (3.25%), Wellington Management Group LLP (1.95%), Segantii Capital Management Ltd (1.81%), Bamco Inc. NY (1.60%), FMR LLC (1.28%) and Rock Springs Capital Management LP (1.25%). Insiders that own company stock include Frazor Titus Edmondson III, Harald Reinhart, John D Diekman, John D Diekman, Joshua L Smiley, Kai-Xian Chen, Peter Wirth, Tao Fu, William Ki Chul Cho, William Lis, Yajing Chen and Ying Du.
View institutional ownership trends
.

How do I buy shares of Zai Lab?

Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ZLAB) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -